PREDQ (Predictive Technology Group) Marketable Securities: $0.00 Mil (As of Mar. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Predictive Technology Group Marketable Securities?

Predictive Technology Group PREDQ -90.00% Marketable Securities is $0.00 Mil as of Mar. 2021.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Predictive Technology Group's Marketable Securities for the quarter that ended in Mar. 2021 was $0.00 Mil.

Predictive Technology Group  (OTCPK:PREDQ) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Predictive Technology Group Marketable Securities Related Terms

Predictive Technology Group Marketable Securities Historical Data

* Premium members only.

The historical data trend for Predictive Technology Group's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Predictive Technology Group Marketable Securities Chart

Predictive Technology Group Annual Data
Trend Aug06 Aug07 Jun16 Jun17 Jun18 Jun19 Jun20
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Predictive Technology Group Quarterly Data
Nov07 Feb08 May08 Jun16 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Predictive Technology Group Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Predictive Technology Group (PREDQ) has a Marketable Securities of $0.00 Mil as of Mar. 2021. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Predictive Technology Group and its competitors.
Is Predictive Technology Group's Marketable Securities too high?
Predictive Technology Group's current Marketable Securities is $0.00 Mil.
How does Predictive Technology Group's Marketable Securities compare to GLMD and RCAR?
Predictive Technology Group's Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Predictive Technology Group and its competitors. Predictive Technology Group's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predictive Technology Group stock overvalued right now?
Predictive Technology Group (PREDQ) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Predictive Technology Group (PREDQ), the current Marketable Securities is $0.00 Mil as of Mar. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Predictive Technology Group Business Description

Address 2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109
Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.